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Clinical and Laboratory Features Distinguishing
Juvenile Polymyositis and Muscular Dystrophy
GULNARA MAMYROVA,1 JAMES D. KATZ,1 ROBERT V. JONES,1 IRA N. TARGOFF,2
PETER A. LACHENBRUCH,3 OLCAY Y. JONES,1 FREDERICK W. MILLER,3 LISA G. RIDER,3 AND THE
CHILDHOOD MYOSITIS HETEROGENEITY COLLABORATIVE STUDY GROUP
Objective. To differentiate juvenile polymyositis (PM) and muscular dystrophy, both of which may present with chronic
muscle weakness and inflammation.
Methods. We studied 39 patients with probable or definite juvenile PM and 9 patients with muscular dystrophies who
were initially misdiagnosed as having juvenile PM. Differences in demographic, clinical, and laboratory results; out-
comes; and treatment responses were evaluated by Fisher’s exact and rank sum tests. Random forests classification
analysis and logistic regression were performed to examine significant differences in multivariable models.
Results. Clinical features and serum muscle enzyme levels were similar between juvenile PM and dystrophy patients,
except 89% of dystrophy patients had muscle atrophy compared with 46% of juvenile PM patients. Dystrophy patients
had a longer delay to diagnosis (median 12 versus 4 months) and were less frequently hospitalized than juvenile PM
patients (22% versus 74%). No dystrophy patients, but 54% of juvenile PM patients, had a myositis autoantibody.
Dystrophy patients more frequently had myopathic features on muscle biopsy, including diffuse variation of myofiber
size, fiber hypertrophy, and myofiber fibrosis (44–100% versus 8–53%). Juvenile PM patients more frequently had
complex repetitive discharges on electromyography and a complete response to treatment with prednisone or other
immunosuppressive agents than dystrophy patients (44% versus 0%). Random forests analysis revealed that the most
important features in distinguishing juvenile PM from dystrophies were myositis autoantibodies, clinical muscle atrophy,
and myofiber size variation on biopsy. Logistic regression confirmed muscle atrophy, myofiber fibrosis, and hospitaliza-
tion as significant predictors.
Conclusion. Muscular dystrophy can present similarly to juvenile PM. Selected clinical and laboratory features are
helpful in combination in distinguishing these conditions.
INTRODUCTION
The juvenile idiopathic inflammatory myopathies (IIMs)
are a rare group of systemic autoimmune disorders char-
acterized by chronic skeletal muscle inflammation of un-
known causes, with onset at age 18 years (1). Although
juvenile dermatomyositis is the primary clinical subgroup
of juvenile IIMs, juvenile polymyositis (PM) has a preva-
lence of 2–8% of all juvenile IIMs (2,3). Juvenile PM can
be more difficult to diagnose because it lacks the charac-
teristic cutaneous manifestations of juvenile dermatomyo-
sitis and has a different distribution of muscle weakness
and myopathologic features (4,5).
Some forms of muscular dystrophies in children can
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mimic juvenile PM. However, juvenile PM and dystro-
phies have different biopsy characteristics, including im-
munopathologic features, but share some common clinical
manifestations (6). The histopathologic hallmark of juve-
nile PM is the presence of endomysial lymphocytic in-
filtration, but muscle inflammation has been reported
in some dystrophies, including Duchenne’s muscular dys-
trophy, facioscapulohumeral muscular dystrophy, limb-
girdle muscular dystrophy type 2B, and congenital mus-
cular dystrophy with primary merosin deficiency (4,6).
Several patients were referred to our studies and clinics
as having juvenile PM. However, upon detailed examina-
tion of their clinical features and review of their muscle
biopsy specimens, followed by immunohistochemical or
genetic testing, they were determined to have muscular
dystrophies. We systematically examined demographic,
clinical, and laboratory results; outcomes; and responses
to therapy of patients with juvenile PM and those misdi-
agnosed with muscular dystrophy to better understand the
distinguishing characteristics of these diseases.
PATIENTS AND METHODS
Patients. Thirty-nine patients with probable or definite
juvenile PM by the Bohan and Peter criteria, defined as
the absence of characteristic skin rashes of dermato-
myositis, including Gottron’s papules and heliotrope
rash (7,8), and 9 patients with muscular dystrophies even-
tually diagnosed by standard clinical/genetic criteria
(9,10) were included. Patients were enrolled in Institu-
tional Review Board–approved natural history protocols
at the National Institutes of Health Clinical Center, Food
and Drug Administration, or George Washington Univer-
sity. The research was performed in accordance with the
ethical standards of the Declaration of Helsinki. Patients
with juvenile PM were diagnosed between 1987 and 2006
and patients with muscular dystrophy were diagnosed
between 1994 and 2009; all were diagnosed before age 18
years. A standardized questionnaire that included demo-
graphic, clinical, and laboratory test results (including
electromyography [EMG], magnetic resonance imaging
[MRI], and muscle biopsy data); treatment responses; and
outcome information was completed by each patient’s
Significance & Innovations
● Muscular dystrophy can present similarly to juve-
nile polymyositis (PM).
● Certain clinical and laboratory features can be
helpful in distinguishing juvenile PM and muscu-
lar dystrophy, including myositis autoantibodies,
as well as less frequent clinical muscle atrophy
and myofiber size variation on muscle biopsy.
Table 1. Demographic and outcome features of patients with juvenile PM
versus muscular dystrophy*
Juvenile PM
(n  39)
Dystrophy
(n  9)
Age at diagnosis, median (IQR) years 12.0 (1.7–18.0) 9.1 (4.4–16.9)
Age at onset, median (IQR) years 11.7 (2.0–16.9) 9.0 (3.0–16.8)
Delay in diagnosis, median (IQR) months 4.0 (1.0–108.0)† 12.0 (0.0–72.0)†
Female sex 30 (76.9) 5 (55.6)
Race
White 19 (48.7) 7 (77.8)
Nonwhite 20 (51.3) 2 (22.2)
Illness onset speed
Insidious (6 months) 15 (38.5) 7 (77.8)
Slow (3–6 months) 11 (28.2) 1 (11.1)
Subacute (1–3 months) 9 (23.1) 0 (0.0)
Acute (1.0 month) 4 (10.3) 1 (11.1)
Disease severity at onset
Mild or moderate 18 (46.2) 6 (66.7)
Severe or very severe 21 (53.8) 3 (33.3)
Family history of autoimmune disease 21 (55.3) 2 (22.2)
Outcome features
Hospitalization 28 (73.7)‡ 2 (22.2)‡
Wheelchair use 8 (20.5) 2 (22.2)
Death 4 (10.5) 0 (0.0)
* Values are the number (percentage) unless indicated otherwise. Percentages may not reflect the number
divided by the total number of subjects when data are missing. PM  polymyositis; IQR  interquartile
range.
† P  0.01.
‡ P  0.007.
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treating physician, with details of the questionnaire and its
definitions explained previously (2,11). Progression of the
first symptoms of illness to full disease presentation was
characterized as acute if it occurred in1 month, subacute
if it occurred in 1–3 months, slow if it occurred over 3–6
months, and insidious if the time to full illness presenta-
tion was 6 months. Severity of illness at onset, up to the
time of diagnosis, was determined by the enrolling physi-
cian and was graded on a 4-point Likert scale from mild to
extremely severe disease activity. Family history of auto-
immune disease was recorded for first- and second-degree
relatives. Muscle enzyme values were adjusted to a com-
mon upper limit of normal, with the highest value re-
corded. Mortality status was established using the Social
Security Death Index, which was last examined in March
2011 (2). Responses to therapy were categorized as com-
plete clinical response if there was no remaining disease
activity after an adequate treatment trial, as defined in the
study by Joffe et al (12), partial clinical response if there
was improvement but not remission, and no clinical re-
sponse if there was no clinical improvement despite an
adequate treatment trial (12).
Thirty-one patients were diagnosed with juvenile PM
only and 8 patients were classified as having juvenile PM
overlapping with a second autoimmune disease; the ma-
jority of patients have been previously reported (2). Among
the 8 patients with overlap myositis, 4 had juvenile PM
overlapping with systemic lupus erythematosus, and 1
each had juvenile PM overlapping with ulcerative colitis,
Sjögren’s syndrome, eosinophilic fasciitis, and juvenile
idiopathic arthritis in combination with Sjögren’s syn-
drome. All juvenile IIM patients had a muscle biopsy
sample consistent with an inflammatory myopathy; the
majority of biopsy specimens were reviewed by 2 myositis
researchers (LGR, FWM), often with pathologists from
the Department of Neuropathology of the Armed Forces
Institute of Pathology, Washington, DC, or by a muscle
pathologist from the Department of Pathology at George
Washington University (RVJ).
All patients with muscular dystrophies were initially
enrolled by the treating physician as having juvenile PM,
and their diagnosis was revised after review of their ques-
tionnaire data and muscle biopsy sample, followed by
specialized immunohistochemical and/or genetic testing
to confirm the specific diagnosis. Through genetic testing
and/or immunohistochemical staining of the muscle bi-
opsy specimen, 1 patient was found to have Duchenne’s
muscular dystrophy, 1 was a carrier for Duchenne’s mus-
cular dystrophy, 2 had facioscapulohumeral muscular
dystrophy, 2 had Emery-Dreifuss dystrophy, 1 had dysfer-
lin dystrophy, 1 had calpain deficiency, and 1 had limb-
girdle dystrophy. Sera were tested for myositis-specific
autoantibodies and myositis-associated autoantibodies by
using validated immunoprecipitation and immunoblotting
methods (13,14).
Statistical analysis. GraphPad Instat for Windows,
version 3.06 (www.graphpad.com) was used for basic sta-
tistical analyses. Summary data were expressed as medi-
ans and interquartile ranges (IQRs), and P values for dif-
ferences between patient groups were obtained by the
Mann-Whitney rank sum test. Fisher’s exact test was used
to compare proportions between groups. A P value of 0.05
or less was considered significant. Because the analyses
were exploratory, correction for multiple comparisons was
not performed. Random forests classification analysis was
performed to further evaluate significant univariate differ-
ences between patients with juvenile PM and those with
dystrophies (15). The random forests classification algo-
rithm was performed using the statistical language R
(version 2.13.1, 2011; http://stat-www.berkeley.edu/users/
breiman/RandomForests/). Due to the difference in sample
size between the groups, the data were resampled to en-
sure balance, using the method of undersampling from the
larger group (15). The statistical model had 500 forests and
20,000 trees per run, and the mean decrease in accuracy
(MDA) was calculated. The mean out-of-bag error rate for
the model was 6.7%. Backward stepwise logistic regres-
Table 2. Clinical features of patients with juvenile PM
versus muscular dystrophy*
Juvenile PM
(n  39)
Dystrophy
(n  9)
Musculoskeletal system
Proximal muscle weakness 39 (100.0) 9 (100.0)
Distal muscle weakness 16 (44.4) 7 (77.8)
Myalgias 25 (64.1) 6 (66.7)
Falling 23 (60.5) 5 (62.5)
Muscle atrophy 17 (45.9)† 8 (88.9)†
Asymmetric weakness 7 (18.4) 3 (33.3)
Arthralgia or arthritis 27 (69.2) 5 (55.6)
Contractures 16 (41.0) 5 (55.6)
Constitutional signs or
symptoms
Fatigue 32 (82.1) 5 (55.6)
Weight loss 21 (53.8) 2 (22.2)
Fever 18 (47.4) 1 (11.1)
Cardiac system
Cardiac abnormalities on
EKG or echocardiogram
14 (36.8) 5 (62.5)
Palpitations 9 (23.1) 1 (11.1)
Gastrointestinal system
Dysphagia 16 (41.0) 1 (11.1)
Abdominal pain 12 (30.8) 3 (33.3)
Regurgitation 6 (15.4) 1 (11.1)
Constipation 3 (7.7) 1 (11.1)
Pulmonary system
Dysphonia 9 (23.7) 1 (11.1)
Interstitial lung disease 7 (17.9) 1 (12.5)
Cutaneous system
Periungual capillary changes 12 (30.8) 0 (0.0)
Raynaud’s phenomenon 11 (28.2) 1 (11.1)
Photosensitivity 2 (5.1) 1 (11.1)
Mechanic’s hands 1 (2.6) 0 (0.0)
Lipodystrophy 0 (0.0) 1 (11.1)
* Values are the number (percentage). Percentages may not reflect
the number divided by the total number of subjects when data are
missing. PM  polymyositis; EKG  electrocardiogram.
† P  0.027.
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sion analysis was also performed with significant variables
from the univariable analysis using Stata, version 12.1.
Variables significant in the univariable analysis with miss-
ing data could not be examined in the random forests
analysis or by logistic regression modeling. Sensitivity,
specificity, and positive and negative predictive values for
juvenile PM versus dystrophy were calculated using the
variables in the final logistic regression model using the
prevalence of juvenile PM in the full sample (0.8).
RESULTS
Patients with muscular dystrophy had a longer delay to
diagnosis (median 12.0 months) than patients with juve-
nile PM (median 4.0 months) (Table 1). There was no
difference in the age at diagnosis or racial distribution
between patients with juvenile PM and muscular dystro-
phy. The female:male ratio was 3.3:1 in the juvenile PM
group compared to 1.3:1 in the dystrophy group. Patients
with dystrophies tended to have a more insidious disease
onset (78% versus 38% in juvenile PM patients; P  0.06)
(Table 1). There was no difference in the frequency of a
family history of autoimmune disease. Hospitalization was
more frequent in patients with juvenile PM compared to
patients with dystrophies (74% versus 22%; P  0.007).
The number of patients reporting use of a wheelchair was
similar. Mortality did not differ between the 2 groups.
Regarding the clinical features of juvenile PM and
muscular dystrophy (Table 2), muscle atrophy was more
frequent in patients with muscular dystrophy (89%)
compared to those with juvenile PM (46%; P  0.027).
Fever occurred more often in juvenile PM patients who
had overlap myositis (62%) than in patients with mus-
cular dystrophy (11%; P  0.05), but was not signifi-
cantly different between the total juvenile PM group (47%)
compared to those with dystrophies. The other reported
clinical features did not differ between the 2 groups of
patients.
Table 3. Laboratory test abnormalities in patients with juvenile PM
versus muscular dystrophy*
Juvenile PM
(n  39)
Dystrophy
(n  9)
Autoantibodies
Antinuclear antibodies 24 (61.5) 3 (33.3)
Any myositis autoantibody 21 (53.8)† 0 (0.0)†
Myositis-specific autoantibodies
Anti–Jo-1 4 (10.3) 0 (0.0)
Anti-SRP 6 (15.4) 0 (0.0)
Myositis-associated autoantibodies‡
Anti–U1 RNP 7 (17.9) 0 (0.0)
Anti-Ro 4 (10.3) 0 (0.0)
Anti-La 2 (5.1) 0 (0.0)
Anti–PM-Scl 2 (5.1) 0 (0.0)
Anti–U2 RNP, anti–TMG cap, anti-Sm (1 each) 3 (7.7) 0 (0.0)
Magnetic resonance imaging
Muscle edema 16 (76.2) 2 (33.3)
Myofasciitis 11 (52.4) 1 (16.7)
Subcutaneous edema 4 (19.0) 1 (16.7)
Muscle atrophy 4 (19.0)§ 5 (83.3)§
Fatty replacement of muscles 5 (23.8) 4 (66.7)
Electromyography
Increased insertional and spontaneous activity
in the form of fibrillation potentials
20 (87.0) 5 (55.6)
Short duration, small amplitude polyphasic
motor unit action potentials
17 (73.9) 7 (77.8)
Complex repetitive discharge 16 (69.6)¶ 2 (22.2)¶
Positive sharp waves 4 (60.9) 3 (33.3)
* Values are the number (percentage). Percentages may not reflect the number divided by the total number
of subjects when data are missing. One patient with anti–Jo-1 also had anti-Ro and anti-La autoantibodies
and another Jo-1–positive patient also had anti–U1 RNP and anti-Sm autoantibodies. Of the myositis-
associated autoantibodies, 1 patient had both anti-Ro and anti-La autoantibodies, 1 patient had anti–U1
RNP and anti-Sm autoantibodies, and 1 patient had anti–U1 RNP, anti–U2 RNP, anti-Ro, anti-La, and
anti–TMG cap autoantibodies. PM  polymyositis; anti-SRP  anti–signal recognition particle; anti-
TMG  anti-trimethylguanosine.
† P  0.003.
‡ Some patients had 1 myositis-associated autoantibody.
§ P  0.008.
¶ P  0.02.
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The frequency of abnormal values and serum muscle
enzyme levels, including creatine kinase, aldolase, lactate
dehydrogenase, and transaminases, and the ratio of aspar-
tate aminotransferase to alanine aminotransferase levels
did not differ between juvenile PM and muscular dystro-
phy patients. For example, the median creatine kinase
level was 7,439 units/liter (IQR 224–53,896) in juvenile
PM patients and 13,541 units/liter (IQR 551–56,941) in
patients with dystrophies (P  0.5). The median aldolase
level was 27 units/liter (IQR 3–217) in juvenile PM pa-
tients and 59 units/liter (IQR 8–1,756) in patients with
dystrophies (P  0.27).
Twenty-four patients (62%) in the juvenile PM group
had a positive antinuclear antibody compared with 3 pa-
tients (33%) in the dystrophy group (Table 3). Patients
with juvenile PM were more frequently positive for one of
the myositis autoantibodies (54%), but none of the dystro-
phy patients had a myositis autoantibody (P  0.003)
(Table 3). Muscle atrophy on MRI of the thighs was more
frequent in patients with muscular dystrophy compared to
patients with juvenile PM (83% versus 19%; P  0.008)
(Table 3). The frequency of other MRI features, including
muscle edema, myofasciitis, subcutaneous edema, and
fatty replacement of the muscles, did not differ between
juvenile PM and dystrophy patients. Complex repetitive
discharges were more often reported in the EMGs of juve-
nile PM patients compared with dystrophy patients (70%
versus 22%; P  0.02). The other EMG features (increased
insertional and spontaneous activity in the form of fibril-
lation potentials, small amplitude polyphasic motor unit
action potentials, and positive sharp waves) did not differ
between the groups.
Comparing the muscle biopsy characteristics of juve-
nile PM and muscular dystrophy patients (Table 4), pa-
tients with dystrophies more often had diffuse variation
of myofiber size (100% versus 53%; P  0.008), as well
as fiber hypertrophy (44% versus 8%; P  0.018) and
myofiber fibrosis (56% versus 10%; P  0.007). Other
histopathologic features on muscle biopsy, including in-
flammatory changes, did not differ between the 2 groups
(Table 4).
In terms of therapy, 1 muscular dystrophy patient was
treated with prednisone alone and 8 were treated with
prednisone in combination with other immunosuppres-
sive agents, whereas 9 juvenile PM patients were treated
with prednisone alone and 30 were treated with a com-
bination of prednisone and other immunosuppressive
agents. Methotrexate alone was the most frequently used
immunosuppressive agent in both juvenile PM patients
(40%) and muscular dystrophy patients (56%). The ab-
sence of a clinical response to treatment was more fre-
quent in patients with dystrophies compared to those
with juvenile PM (33% versus 0.0%; P  0.005). There
were no differences in the frequency of partial clinical
responses to treatment. None of the dystrophy patients
had a complete response to therapy, whereas 43.6% of
patients with juvenile PM had a complete clinical re-
sponse (P  0.018).
Random forests analysis was used to examine the 9
distinguishing features between juvenile PM and dystro-
phies that were significant on univariate analysis and for
which no data were missing; 3 juvenile PM patients were
excluded from this analysis due to missing variables. Ran-
dom forests analysis revealed that myositis autoanti-
bodies were best for discriminating juvenile PM from dys-
trophies (average MDA score 100.0), followed by clinical
muscle atrophy (MDA 45.0), diffuse variation in myofiber
size (MDA 35.9), and total response to immunosuppres-
sive therapy (MDA 32.0).
Multivariate logistic regression analysis revealed that
more frequent hospitalization (odds ratio [OR] 32.8, 95%
confidence interval [95% CI] 2.2–478.5), less frequent
myofiber fibrosis on biopsy (OR 0.06, 95% CI 0.004–0.77),
and less frequent muscle atrophy on examination (OR
0.067, 95% CI 0.033–1.21) were significant predictors of
juvenile PM compared to dystrophy. Because none of the
dystrophy patients had a myositis autoantibody, a point
estimate could not be obtained for this variable. The fi-
nal multivariable model using hospitalization, myofiber
fibrosis on biopsy, and clinical muscle atrophy provided
a sensitivity of 91.4% and a specificity of 77.8% for de-
tecting juvenile PM versus dystrophy, with a positive pre-
Table 4. Muscle biopsy features of patients with
juvenile PM versus muscular dystrophy*
Juvenile PM
(n  39)
Dystrophy
(n  9)
Endomysial infiltration of
mononuclear cells surrounding
but not invading myofibers
23 (60.5) 5 (55.6)
Non-necrotic myofibers surrounded
and invaded by mononuclear
cells
3 (7.9) 0 (0.0)
Perimysial and/or perivascular
infiltration of mononuclear cells
26 (68.4) 3 (33.3)
Phagocytosis 9 (23.7) 2 (22.2)
Presence of macrophages/
histiocytes
13 (34.2) 2 (22.2)
Myofasciitis 2 (5.3) 1 (11.1)
Myofiber degeneration/regeneration 25 (65.8) 7 (77.8)
Necrosis of type I and type II
myofibers
15 (39.5) 2 (22.2)
Many necrotic muscle fibers as
the predominant feature;
inflammatory cells are sparse
3 (7.9) 1 (11.1)
Diffuse variation of myofiber size 20 (52.6)† 9 (100.0)†
Rounded fiber at the edge of the
fascicle
6 (15.8) 1 (11.1)
Fiber hypertrophy 3 (7.9)‡ 4 (44.4)‡
Hypercontracted fibers 2 (5.3) 1 (11.1)
Perifascicular atrophy 12 (31.6) 1 (11.1)
Myofiber fibrosis 4 (10.5)§ 5 (55.6)§
Fiber fatty replacement 1 (2.6) 2 (22.2)
* Values are the number (percentage). Percentages may not reflect
the number divided by the total number of subjects when data are
missing. PM  polymyositis.
† P  0.008.
‡ P  0.018.
§ P  0.007.
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dictive value of 94.1% and a negative predictive value of
70.0%.
DISCUSSION
Distinguishing between juvenile PM and muscular dystro-
phies can be clinically challenging, since both conditions
are characterized by the presence of chronic muscle weak-
ness and inflammation and share a number of clinical
features. As demonstrated here, 9 muscular dystrophy pa-
tients were initially misdiagnosed as having juvenile PM
and were correctly diagnosed only after further careful
evaluation, including eventual pathologic or genetic test-
ing. We systematically examined many different charac-
teristics of patients with juvenile PM or defined muscular
dystrophies, including demographics, clinical findings,
laboratory results, outcomes, and treatment responses, to
identify distinguishing features of these conditions.
Compared to patients with juvenile PM, patients with
dystrophies had more frequent muscle atrophy clinically
and on MRI, did not have myositis autoantibodies, and
had certain myopathic muscle biopsy findings more fre-
quently, including the presence of diffuse variation of
myofiber size, fiber hypertrophy, and myofiber fibrosis.
Patients with juvenile PM, in contrast, were more often
hospitalized and more frequently had a clinical response
to treatment with prednisone and/or other immunosup-
pressive agents.
Many of the clinical and demographic features and
the serum muscle enzyme levels were indistinguishable
between juvenile PM and dystrophy patients. This sug-
gests that further investigation and careful evaluation are
needed for children presenting with muscle weakness and
enzyme changes without the characteristic skin rashes of
juvenile dermatomyositis. The level of creatine kinase el-
evation (16) or the presence of muscle edema on MRI
(17,18) has been noted to be similar in adult patients with
PM and dystrophies, as we also observed in this pediatric
study. We did not have information on other inflammatory
markers, such as neopterin or von Willebrand factor anti-
gen level (1), and differences in these variables between
patients with juvenile PM and dystrophies. Endomysial
lymphocytic infiltrates, considered to be a hallmark of PM,
are frequently present in certain dystrophies (19,20). We
did not observe differences in the inflammatory features of
the muscle biopsy samples of juvenile PM and dystrophy
patients.
Some of the features we found that differentiate juvenile
PM from muscular dystrophies have been noted individ-
ually by others in distinguishing adult PM from dystro-
phies, based on case reports and limited clinical experi-
ence, or based on examination of a single laboratory test,
rather than from a systematic investigation such as this
one. Prior distinctions between PM and dystrophies have
included a slower rate of progression and lack of response
to immunosuppressive therapy in dystrophy patients
(17,19,20), as well as a stronger family history of auto-
immune disease in patients with IIMs (21). The higher
frequency of a positive antinuclear antibody test and the
presence of myositis autoantibodies in patients with PM
and not in patients with dystrophies also have been ob-
served previously (17,22,23) and were confirmed here.
Patients with dystrophies often have weakness in other
muscle groups or additional clinical manifestations, such
as muscle hypertrophy, scapular winging, spinal rigidity,
and macroglossia, which are absent in patients with PM,
and they may have a family history of muscle disease
(24,25). However, those features were not part of our ques-
tionnaire and therefore could not be assessed.
The differences in the biopsy features that we observed
included the myopathic features, which were more fre-
quent in the dystrophy group, including myofiber size
variation, fiber hypertrophy, and hypercontracted fibers.
In a previous study in which 13 patients were misdiag-
nosed with juvenile PM and had undetected dystrophies,
the distinguishing biopsy features in patients with dystro-
phies included subsarcolemmal blebbing, isolated fiber
degeneration without accompanying inflammation, and a
perimysial infiltrate consisting of macrophages (6). We did
not find differences in these latter biopsy features in this
study and did not examine subsarcolemmal blebbing. The
presence of diffuse class I major histocompatibility com-
plex (class I MHC) antigen expression on the sarcolemma
of muscle fibers is an important feature for distinguishing
inflammatory from noninflammatory myopathies (26–28).
However, class I MHC antigen staining of myofibers has
also been described in some forms of dystrophies, includ-
ing dysferlinopathies and Duchenne’s muscular dystrophy
(29). We did not have access to class I MHC staining. The
common biopsy features of juvenile PM included not only
endomysial inflammation, but also the frequent presence
of perimysial and/or perivascular inflammation, myofiber
degeneration/regeneration, and even perifascicular atro-
phy, which are thought to be characteristic of dermato-
myositis (30).
A strength of our study is the simultaneous examina-
tion of many features of similar, and often misdiagnosed,
muscle diseases to determine which are most strongly
associated with juvenile PM versus the dystrophies. How-
ever, because not all patients had an MRI or EMG exami-
nation, we were unable to analyze these particular test
results in multivariable modeling. We were also unable to
examine differences in the time to treatment responses
because of an absence of detailed response to therapy data
over time. Due to the rarity of these conditions, the small
sample sizes also limited the power of the multivariable
modeling and the overall study. The population of patients
studied also may have potential selection bias, in that the
majority of patients were submitted by rheumatologists.
Given the multiple comparisons made, the findings would
be susceptible to Type I error, although this is preferred
to avoid rejecting the null hypothesis too readily in explor-
atory analyses (31). Future studies are needed to confirm
the robustness of these data when applied to a larger
population.
In conclusion, muscular dystrophy can present clini-
cally very similarly to juvenile IIM, particularly juvenile
PM. Specific clinical findings, responses to immunosup-
pressive therapies, and laboratory test results help distin-
guish muscular dystrophy and juvenile PM.
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Terri H. Finkel, Ellen A. Goldmuntz, Gary V. Gordon, Brandt P.
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Russell J. Hopp, Norman T. Ilowite, Jerry C. Jacobs (deceased),
Lisa Imundo, Andrew Lasky, Katherine Madson, Ann M. Neumeyer,
Judyann C. Olson, Barbara E. Ostrov, Lauren M. Pachman,
Ramesh Pappu, Maria D. Perez, Karin S. Peterson, Paul H. Plotz,
Marilynn G. Punaro, Charles D. Radis, Linda I. Ray, Robert M.
Rennebohm, Peter D. Reuman, Deborah Rothman, Robert Sheets,
David D. Sherry, Carol A. Wallace, and Patience H. White.
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